CS
CRNX icon

Credit Suisse’s Crinetics Pharmaceuticals CRNX Stock Holding History

Credit Suisse’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$2.82M Buy
60,287
+11,044
+22% +$432K ﹤0.01% 1641
2023
Q4 		$1.75M Buy
49,243
+12,036
+32% +$369K ﹤0.01% 1974
2023
Q3 		$1.11M Sell
37,207
-5,589
-13% -$115K ﹤0.01% 2238
2023
Q2 		$771K Buy
42,796
+11,076
+35% +$221K ﹤0.01% 2562
2023
Q1 		$509K Buy
31,720
+2,038
+7% +$37.7K ﹤0.01% 2745
2022
Q4 		$543K Sell
29,682
-1,384
-4% -$24.4K ﹤0.01% 2732
2022
Q3 		$611K Buy
31,066
+3,630
+13% +$74K ﹤0.01% 2674
2022
Q2 		$511K Buy
27,436
+2,506
+10% +$50K ﹤0.01% 2821
2022
Q1 		$547K Buy
24,930
+4,613
+23% +$93.4K ﹤0.01% 2916
2021
Q4 		$577K Buy
20,317
+5,935
+41% +$146K ﹤0.01% 3708
2021
Q3 		$304K Buy
14,382
+92
+0.6% +$1.92K ﹤0.01% 4082
2021
Q2 		$269K Buy
14,290
+3,798
+36% +$66.7K ﹤0.01% 4160
2021
Q1 		$160K Sell
10,492
-7,978
-43% -$124K ﹤0.01% 4155
2020
Q4 		$261K Buy
+18,470
New +$257K ﹤0.01% 4026
2020
Q3 		– Sell
-12,057
Closed -$211K – 4036
2020
Q2 		$211K Buy
+12,057
New +$206K ﹤0.01% 3713

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Credit Suisse's CRNX Position: Q1 2024 in Review

Credit Suisse increased its Crinetics Pharmaceuticals (CRNX) stake by 22% in Q1 2024, buying an estimated $432K and bringing the position to 60,287 shares worth $2.82M. The position accounts for ﹤0.01% of the portfolio, ranked #1641.

Credit Suisse first reported a position in CRNX in Q2 2020 and has held it in 15 quarters since. 203 funds tracked by Wall St. Rank hold CRNX as of Q1 2024.

  • Credit Suisse held 60,287 shares of Crinetics Pharmaceuticals worth $2.82M as of Q1 2024.
  • Credit Suisse bought 11,044 Crinetics Pharmaceuticals shares in Q1 2024, an estimated $432K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1641 holding.
  • Credit Suisse first reported a position in Crinetics Pharmaceuticals in Q2 2020 and has held it in 15 quarters since.
  • 203 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.